MPs to examine impact of NICE changes on ‘last resort’ cancer drug treatments
The committee will consider the impact of changes made by NICE to evaluate drugs used to treat patients with terminal illness like cancer in this session.
Meeting details
At 9:30am: Oral evidence
Work
Future Cancer: NICE medicines appraisal (Enhertu) (Non-inquiry session)
Head of Oncology at AstraZeneca UK
Vice President, Oncology at Daiichi Sankyo UK
At 10:15am: Oral evidence
Work
Future Cancer: NICE medicines appraisal (Enhertu) (Non-inquiry session)
Chief Executive at Breast Cancer Now
At 10:45am: Oral evidence
Work
Future Cancer: NICE medicines appraisal (Enhertu) (Non-inquiry session)
Director of Medicines Evaluation at National Institute for Health and Care Excellence (NICE)
Chief Executive at National Institute for Health and Care Excellence (NICE)
The Future Cancer inquiry received evidence from drugs’ companies that changes by NICE in 2022 on the cost-effectiveness of drugs for severe diseases do not sufficiently weight treatments used in advanced cancer. They say that as a result some cancer patients may miss out on last resort treatments.
MPs will also consider the breast cancer drug Enhertu which, in draft guidance from NICE, has not been recommended for treating secondary breast cancer in England.
The APPG on Breast Cancer will hold a roundtable event focusing on this issue later the same day.